Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
暂无分享,去创建一个
Martin Dugas | Hans-Ulrich Klein | Torsten Haferlach | Wolfgang Kern | Tamara Weiss | Susanne Schnittger | Alexander Kohlmann | Vera Grossmann | Claudia Haferlach | Frank Dicker | A. Kohlmann | T. Haferlach | S. Schnittger | W. Kern | H. Klein | C. Haferlach | T. Weiss | M. Dugas | V. Grossmann | Sonja Schindela | Beray Kazak | F. Dicker | S. Schindela | B. Kazak
[1] Thomas LaFramboise,et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[2] K. Voelkerding,et al. Next-generation sequencing: from basic research to diagnostics. , 2009, Clinical chemistry.
[3] T. Haferlach,et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. , 2007, Haematologica.
[4] D. Birnbaum,et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.
[5] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[6] R. Levine,et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. , 2009, Blood.
[7] D. Loegering,et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. , 2009, Blood.
[8] D. Gilliland,et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.
[9] J. Bennett,et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. , 2007, Haematologica.
[10] A. Hall,et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.
[11] Terry L. Smith,et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.
[12] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.
[13] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[14] J. Cortes. CMML: a biologically distinct myeloproliferative disease. , 2003, Current hematology reports.
[15] M. McDevitt,et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.
[16] D. Gilliland,et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.
[17] P. F. di Celle,et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia , 2009, Journal of Clinical Pathology.
[18] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[19] D. Birnbaum,et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes , 2008, BMC Cancer.
[20] J. Jelinek,et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System , 2007, Leukemia & lymphoma.
[21] E. Estey,et al. Prognostic significance of monocytosis in patients with myeloproliferative disorders , 2006, Leukemia & lymphoma.
[22] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[23] G. Martinelli,et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia , 2008, Leukemia.
[24] Herbert Begemann,et al. Atlas of Clinical Hematology , 1979, Springer Berlin Heidelberg.
[25] U. Germing,et al. Risk Assessment in Chronic Myelomonocytic Leukemia (CMML) , 2004, Leukemia & lymphoma.
[26] O. Bernard,et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias , 2010, Leukemia.
[27] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[28] U. Germing,et al. New prognostic parameters for chronic myelomonocytic leukemia. , 2002, Blood.
[29] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[30] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[31] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.